Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Fig. 2

Kaplan–Meier curves for progression-free survival

Group 1: 19 patients who received adequate durvalumab dosing

Group 2: 7 patients who could not receive durvalumab after its approval, and 4 patients who received ≤ 3 cycles of durvalumab

Group 3: 21 patients who did not receive durvalumab because it had not yet been approved

PFS, progression-free survival; CRT, chemoradiotherapy

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us